Human immunodeficiency virus viral load suppression and associated factors among client on anti-retroviral therapy in asella teaching and referral hospital, Ethiopia
The goal of therapy following treatment failure is toachieve and maintain Virological suppressions via the three 90 target by the year 2020 to accelerate reaching epidemic control of those on Anti-Retroviral Therapy (ART) shall be virally suppressed. Therefore, the aimed of this study to assess Human Immunodeficiency Virus(HIV) on High viral load suppression and associated factors among client on ART in Asella Teaching and Referral Hospital, Arsi Zone, Oromia Regional State, Ethiopia, 2019. Institution based cross sectional study was conducted by chart review. A total of 430 study subjects were selected with complete information included in the analysis. The collected data was entered in to Epi info Version 7 software then cleaned data was exported to SPSS version 21 for analysis. All explanatory variables with at p-value<0.2 in the crude analysis were included in the multiple logistic regression analysis with 95% CI computed. A P-value<0.05 has considered statistically significant. A total of 430 people living with HIV enrolled in this study was, 356 (82.8%) had not suppressed viral load with the corresponding 95% confidence interval was (79.2, 86.3). People living with HIV enrolled with '''baseline Hgb < 10g/dl [AOR=1.834,95% CI(1.407,2.710)], patients hav.ing poor adherence [AOR=15.204, 95%CI (8.087, 28.58)] and patients enrolled to care who use substance [ AOR=1.6,95%CI (1.021,3.118)] were at risky to get high viral load. The findings of this study strongly indicated that on treatment viral load suppression rates 17.2% patients had suppressed viral load < 1000 RNAcopies/mL. This proportion falls short of the UNAIDS’ 90% target for on treatment viral suppression. Poor adherence, Hgb level < 10g/dl and substance use were factors that decreases rates of viral load suppression. Therefore, the Human Immunodeficiency Virus(HIV) treatment program me can maintain and potentially improve virological treatment outcomes by improving access to targeted viral load testing.
